Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$33.34
+0.5%
$27.20
$14.80
$40.47
$2.53B0.87823,360 shs1.40 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$10.02
-4.0%
$12.00
$5.00
$16.85
$618.04M1.51.57 million shs1.46 million shs
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$60.29
+0.6%
$59.06
$1.16
$14.10
$2.61B-0.12189,291 shs150,749 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$25.31
-1.2%
$30.52
$24.07
$55.33
$1.55B2.311.31 million shs1.50 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
-1.40%+7.18%+32.91%+28.23%-9.15%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
+2.08%-10.28%-9.28%+17.02%+67.90%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-0.66%-2.68%+2.30%+13.72%+20.99%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+6.00%-0.08%-6.70%-23.60%-42.27%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$33.34
+0.5%
$27.20
$14.80
$40.47
$2.53B0.87823,360 shs1.40 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$10.02
-4.0%
$12.00
$5.00
$16.85
$618.04M1.51.57 million shs1.46 million shs
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$60.29
+0.6%
$59.06
$1.16
$14.10
$2.61B-0.12189,291 shs150,749 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$25.31
-1.2%
$30.52
$24.07
$55.33
$1.55B2.311.31 million shs1.50 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
-1.40%+7.18%+32.91%+28.23%-9.15%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
+2.08%-10.28%-9.28%+17.02%+67.90%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-0.66%-2.68%+2.30%+13.72%+20.99%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+6.00%-0.08%-6.70%-23.60%-42.27%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.92
Moderate Buy$53.9161.69% Upside
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
2.33
Hold$9.50-5.19% Downside
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.73
Moderate Buy$49.4095.18% Upside

Current Analyst Ratings Breakdown

Latest DNA, TWST, GMTX, and CGON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Jones Trading
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$50.00
9/8/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$75.00
9/5/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$75.00
9/1/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
8/25/2025
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSell$6.00 ➝ $9.00
8/18/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$55.00
8/8/2025
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$46.00
7/16/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$68.00 ➝ $53.00
7/10/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy$40.00
(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$1.14M2,229.98N/AN/A$9.63 per share3.46
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$227.04M2.61N/AN/A$13.17 per share0.76
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M4.88N/AN/A$8.07 per share3.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$88.04M-$1.77N/AN/AN/A-15,945.17%-19.37%-18.72%11/11/2025 (Estimated)
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$547.03M-$5.86N/AN/AN/A-136.56%-43.25%-22.29%11/11/2025 (Estimated)
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$1.45N/AN/AN/A-23.51%-29.03%-21.77%11/17/2025 (Estimated)

Latest DNA, TWST, GMTX, and CGON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.49-$0.54-$0.05-$0.54$0.11 millionN/A
8/7/2025Q2 2025
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$1.44-$1.10+$0.34-$1.10$41.60 million$49.60 million
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54-$0.47+$0.07$0.33$95.52 million$96.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
22.15
22.15
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
5.41
5.41
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
3.90
3.60

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
75.42%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
7.40%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
9.72%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
12.90%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6176.25 million70.61 millionOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
64059.20 million53.45 millionOptionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99060.36 million58.54 millionOptionable

Recent News About These Companies

Twist Bioscience (NASDAQ:TWST) Sets New 1-Year Low on Insider Selling
Twist Bioscience (NASDAQ:TWST) Trading Down 5.4% - What's Next?
Invesco Small Cap Growth Fund Q2 2025 Commentary
Twist Bioscience Collaborates with Synthetic Design Lab

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$33.34 +0.18 (+0.54%)
Closing price 04:00 PM Eastern
Extended Trading
$33.36 +0.02 (+0.06%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$10.02 -0.42 (-4.02%)
Closing price 03:59 PM Eastern
Extended Trading
$10.05 +0.03 (+0.26%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$60.29 +0.35 (+0.58%)
As of 09/11/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$25.31 -0.30 (-1.17%)
Closing price 04:00 PM Eastern
Extended Trading
$25.58 +0.27 (+1.05%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.